These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 34729375)

  • 1. CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.
    Demirci S; Leonard A; Essawi K; Tisdale JF
    Mol Ther Methods Clin Dev; 2021 Dec; 23():276-285. PubMed ID: 34729375
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome editing strategies for fetal hemoglobin induction in beta-hemoglobinopathies.
    Demirci S; Leonard A; Tisdale JF
    Hum Mol Genet; 2020 Sep; 29(R1):R100-R106. PubMed ID: 32406490
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A genome-editing strategy to treat β-hemoglobinopathies that recapitulates a mutation associated with a benign genetic condition.
    Traxler EA; Yao Y; Wang YD; Woodard KJ; Kurita R; Nakamura Y; Hughes JR; Hardison RC; Blobel GA; Li C; Weiss MJ
    Nat Med; 2016 Sep; 22(9):987-90. PubMed ID: 27525524
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Combined approaches for increasing fetal hemoglobin (HbF) and
    Finotti A; Gambari R
    Front Genome Ed; 2023; 5():1204536. PubMed ID: 37529398
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysis.
    Quagliano A; Acevedo D; Hardigan P; Prasad S
    Front Med (Lausanne); 2022; 9():943631. PubMed ID: 36250099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
    Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
    Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Editing the core region in HPFH deletions alters fetal and adult globin expression for treatment of β-hemoglobinopathies.
    Venkatesan V; Christopher AC; Rhiel M; Azhagiri MKK; Babu P; Walavalkar K; Saravanan B; Andrieux G; Rangaraj S; Srinivasan S; Karuppusamy KV; Jacob A; Bagchi A; Pai AA; Nakamura Y; Kurita R; Balasubramanian P; Pai R; Marepally SK; Mohankumar KM; Velayudhan SR; Boerries M; Notani D; Cathomen T; Srivastava A; Thangavel S
    Mol Ther Nucleic Acids; 2023 Jun; 32():671-688. PubMed ID: 37215154
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical genome editing to treat sickle cell disease-A brief update.
    Zarghamian P; Klermund J; Cathomen T
    Front Med (Lausanne); 2022; 9():1065377. PubMed ID: 36698803
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Genome editing approaches to β-hemoglobinopathies.
    Brusson M; Miccio A
    Prog Mol Biol Transl Sci; 2021; 182():153-183. PubMed ID: 34175041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
    Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
    Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Induction of Fetal Hemoglobin by Introducing Natural Hereditary Persistence of Fetal Hemoglobin Mutations in the γ-Globin Gene Promoters for Genome Editing Therapies for β-Thalassemia.
    Lu D; Xu Z; Peng Z; Yang Y; Song B; Xiong Z; Ma Z; Guan H; Chen B; Nakamura Y; Zeng J; Liu N; Sun X; Chen D
    Front Genet; 2022; 13():881937. PubMed ID: 35656314
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
    Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
    Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Optimization of CRISPR/Cas9 Delivery to Human Hematopoietic Stem and Progenitor Cells for Therapeutic Genomic Rearrangements.
    Lattanzi A; Meneghini V; Pavani G; Amor F; Ramadier S; Felix T; Antoniani C; Masson C; Alibeu O; Lee C; Porteus MH; Bao G; Amendola M; Mavilio F; Miccio A
    Mol Ther; 2019 Jan; 27(1):137-150. PubMed ID: 30424953
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Fetal Hemoglobin in Sickle Hemoglobinopathies: High HbF Genotypes and Phenotypes.
    Steinberg MH
    J Clin Med; 2020 Nov; 9(11):. PubMed ID: 33238542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and efficacy studies of CRISPR-Cas9 treatment of sickle cell disease highlights disease-specific responses.
    Frati G; Brusson M; Sartre G; Mlayah B; Felix T; Chalumeau A; Antoniou P; Hardouin G; Concordet JP; Romano O; Turchiano G; Miccio A
    Mol Ther; 2024 Dec; 32(12):4337-4352. PubMed ID: 39044427
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Detection of CRISPR/Cas9-Mediated Fetal Hemoglobin Reactivation in Erythroblasts Derived from Cord Blood-Hematopoietic Stem Cells.
    Maroofi N; Maleki MSM; Tahmasebi M; Khorshid HRK; Modaberi Y; Najafipour R; Banan M
    Mol Biotechnol; 2024 Apr; ():. PubMed ID: 38649638
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly efficient therapeutic gene editing of human hematopoietic stem cells.
    Wu Y; Zeng J; Roscoe BP; Liu P; Yao Q; Lazzarotto CR; Clement K; Cole MA; Luk K; Baricordi C; Shen AH; Ren C; Esrick EB; Manis JP; Dorfman DM; Williams DA; Biffi A; Brugnara C; Biasco L; Brendel C; Pinello L; Tsai SQ; Wolfe SA; Bauer DE
    Nat Med; 2019 May; 25(5):776-783. PubMed ID: 30911135
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Co-Treatment of Erythroid Cells from β-Thalassemia Patients with CRISPR-Cas9-Based β
    Cosenza LC; Zuccato C; Zurlo M; Gambari R; Finotti A
    Genes (Basel); 2022 Sep; 13(10):. PubMed ID: 36292612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.